Tranexamic acid versus kojic acid in facial post-inflammatory hyperpigmentation following acne: a narrative review

Sanjana R. Tummala; Swetha Donakonda; B. Uday Kumar

doi:10.18203/issn.2455-4529.IntJResDermatol20262352

Authors

Sanjana R. Tummala Department of Dermatology, MNR Medical College and Hospital, Sangareddy, Telangana, India
Swetha Donakonda Department of Dermatology, MNR Medical College and Hospital, Sangareddy, Telangana, India
B. Uday Kumar Department of Dermatology, MNR Medical College and Hospital, Sangareddy, Telangana, India

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20262352

Keywords:

Tranexamic acid, Kojic acid, Post-inflammatory hyperpigmentation, Acne vulgaris, Facial hyperpigmentation, Skin of colour

Abstract

Facial post-inflammatory hyperpigmentation (PIH) following acne is a frequent and distressing sequela, especially in darker Fitzpatrick skin phototypes. Tranexamic acid (TXA) and kojic acid are increasingly used as non-hydroquinone depigmenting agents, but their comparative role in acne-induced PIH remains insufficiently defined. Objective of the study was to compare the mechanistic rationale, clinical evidence, safety profile, and practical role of TXA versus kojic acid in facial PIH after acne. A focused narrative review was performed using DOI-traceable studies and reviews on acne-induced PIH, TXA, kojic acid, and facial hyperpigmentation. Evidence from acne-specific PIH studies was prioritized, while melasma studies were used only as indirect supportive evidence because melasma and PIH differ in pathogenesis. Acne-induced PIH is driven by inflammation-mediated melanocyte stimulation, excess epidermal melanin, and, in some cases, dermal melanophages. TXA acts upstream by inhibiting plasminogen activation and reducing inflammatory and vascular mediators involved in melanogenesis. Clinical evidence for TXA in PIH includes systematic review data and a randomized trial showing topical 5% TXA to be comparable to 20% azelaic acid for acne-related PIH, with favourable early tolerability. Kojic acid acts mainly by copper chelation and tyrosinase inhibition. Its evidence in acne-PIH is more limited, with small preliminary data in post-acne hyperpigmentation and stronger indirect evidence from melasma studies, often in combination with hydroquinone, glycolic acid, or vitamin C. No robust direct head-to-head trial of TXA versus kojic acid for facial post-acne PIH was identified. Current evidence supports both agents as useful non-hydroquinone options. TXA may be preferable where inflammation, erythema, recurrence, or sensitive skin are prominent, while kojic acid may be useful for epidermal brown macular pigmentation in patients tolerating tyrosinase inhibitors. Direct comparative randomized trials are needed.

References

Auffret N, Leccia MT, Ballanger F, Claudel JP, Dahan S, Dréno B. Acne-induced post-inflammatory hyperpigmentation: from grading to treatment. Acta Derm Venereol. 2025;105:adv42925.

Abad-Casintahan F, Chow SKW, Goh CL, Kubba R, Hayashi N, Noppakun N, et al. Frequency and characteristics of acne-related post-inflammatory hyperpigmentation. J Dermatol. 2016;43(7):826-8.

Abanmi A, Al-Enezi M, Al Hammadi A, Galadari I, Kibbi AG, Zimmo S. Survey of acne-related post-inflammatory hyperpigmentation in the Middle East. J Dermatolog Treat. 2019;30(6):578-81.

Taylor SC, Cook-Bolden F, Rahman Z, Strachan D. Acne vulgaris in skin of color. J Am Acad Dermatol. 2002;46(2 Suppl):S98-106.

Al-Qarqaz F, Bodoor K, Baba A, Al-Yousef A, Muhaidat J, Alshiyab D. Post-acne hyperpigmentation: evaluation of risk factors and the use of artificial neural network as a predictive classifier. Dermatol Rep. 2021;13(3):8223.

Elbuluk N, Grimes P, Chien A, Hamzavi I, Alexis A, Taylor S, et al. The pathogenesis and management of acne-induced post-inflammatory hyperpigmentation. Am J Clin Dermatol. 2021;22(6):829-36.

Taylor S, Elbuluk N, Grimes P, Chien A, Hamzavi I, Alexis A, et al. Treatment recommendations for acne-associated hyperpigmentation: results of the Delphi consensus process and a literature review. J Am Acad Dermatol. 2023;89(2):316-23.

Kashetsky N, Feschuk A, Pratt ME. Post-inflammatory hyperpigmentation: a systematic review of treatment outcomes. J Eur Acad Dermatol Venereol. 2024;38(3):470-9.

Sobhan M, Talebi-Ghane E, Poostiyan E. A comparative study of 20% azelaic acid cream versus 5% tranexamic acid solution for the treatment of postinflammatory hyperpigmentation in patients with acne vulgaris: a single-blinded randomized clinical trial. J Res Med Sci. 2023;28:18.

Alsharif SH, Alghamdi AS, Alwayel ZA, Alaklabi SN, Alyamani NA, Sabsabee MA, et al. Efficacy and best mode of delivery for tranexamic acid in post-inflammatory hyperpigmentation: a systematic review. Clin Cosmet Investig Dermatol. 2022;15:2873-82.

Kim JK, Chang SE, Won CH, Lee MW, Choi JH, Moon KC. Dramatic improvement of long lasting post-inflammatory hyperpigmentation by oral and topical tranexamic acid. J Cosmet Dermatol Sci Appl. 2012;2(2):62-3.

Lee YB, Park SM. Combination treatment of low-fluence Q-switched Nd:YAG laser and oral tranexamic acid for post-inflammatory hyperpigmentation due to allergic contact dermatitis to henna hair dye. J Cosmet Laser Ther. 2016;18(2):95-7.

Chen T, Xue J, Wang Q. Tranexamic acid for the treatment of hyperpigmentation and telangiectatic disorders other than melasma: an update. Clin Cosmet Investig Dermatol. 2024;17:2151-63.

Janney MS, Subramaniyan R, Dabas R, Lal S, Das NM, Godara SK. A randomized controlled study comparing the efficacy of topical 5% tranexamic acid solution versus 3% hydroquinone cream in melasma. J Cutan Aesthet Surg. 2019;12(1):63-7.

Atefi N, Dalvand B, Ghassemi M, Mehran G, Heydarian AA. Therapeutic effects of topical tranexamic acid in comparison with hydroquinone in treatment of women with melasma. Dermatol Ther (Heidelb). 2017;7(3):417-24.

Kanechorn Na Ayuthaya P, Niumphradit N, Manosroi A, Nakakes A. Topical 5% tranexamic acid for the treatment of melasma in Asians: a double-blind randomized controlled clinical trial. J Cosmet Laser Ther. 2012;14(3):150-4.

Lim JTE. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg. 1999;25(4):282-4.

Monteiro RC, Kishore BN, Bhat RM, Sukumar D, Martis J, Ganesh HK. A comparative study of the efficacy of 4% hydroquinone vs 0.75% kojic acid cream in the treatment of facial melasma. Indian J Dermatol. 2013;58(2):157.

Wawrzyk-Bochenek I, Rahnama M, Stachura M, Wilczyński S, Wawrzyk A. Evaluation of the reduction of skin hyperpigmentation changes under the influence of a preparation containing kojic acid using hyperspectral imaging—preliminary study. J Clin Med. 2023;12(7):2710.

Saeedi M, Eslamifar M, Khezri K. Kojic acid applications in cosmetic and pharmaceutical preparations. Biomed Pharmacother. 2019;110:582-93.